MicroVision, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $12.2 million for the third quarter and a nine-month net loss of $74.5 million, alongside a significant increase in revenue compared to the prior-year period.

Key Highlights

  • Q3 2026 revenue of $2,400 thousand, up from $241 thousand in Q3 2025, according to the filing.
  • Nine-month net loss of $74,465 thousand ($3.18 per share, basic and diluted), compared to a loss of $57,225 thousand ($3.27 per share) in the same period of 2025.
  • Total assets of $90,829 thousand as of September 30, 2026, down from $103,119 thousand at December 31, 2025.
  • Cash and cash equivalents of $28,890 thousand as of September 30, 2026, compared to $32,363 thousand at December 31, 2025; available-for-sale investment securities dropped to zero from $42,471 thousand.
  • Common shares outstanding rose to 32,430 thousand as of September 30, 2026, from 20,434 thousand at December 31, 2025, reflecting common stock sales and note conversions.
  • Notes payable of $22,595 thousand and a derivative liability of $6,331 thousand appeared among current liabilities as of September 30, 2026.
  • Accumulated deficit reached $1,031,727 thousand as of September 30, 2026, up from $957,262 thousand at December 31, 2025.

MicroVision Reports Widening Losses and Balance Sheet Changes Through September 2026

According to the filing, MicroVision reported revenue of $2,400 thousand for the three months ended September 30, 2026, compared to $241 thousand for the same quarter in 2025. For the nine months ended September 30, 2026, revenue was $4,808 thousand, versus $985 thousand in the prior-year period. Gross profit for Q3 2026 was $1,199 thousand, compared to a gross loss of $716 thousand in Q3 2025. For the nine-month period, gross profit was $2,204 thousand, against a gross loss of $1,238 thousand in 2025.

The filing reported total operating expenses of $22,536 thousand for Q3 2026, driven by research and development expense of $13,180 thousand and sales, marketing, general and administrative expense of $9,359 thousand. Loss from operations for the quarter was $21,337 thousand. For the nine-month period, total operating expenses were $71,246 thousand, producing a loss from operations of $69,042 thousand. The filing also noted a realized loss on debt extinguishment of $3,083 thousand and an unrealized loss on derivative liability of $5,146 thousand for the nine months ended September 30, 2026, partially offset by an unrealized gain on warrant liability of $5,061 thousand and other income of $8,134 thousand.

On the balance sheet, the company disclosed goodwill of $3,677 thousand and intangible assets, net of $13,358 thousand as of September 30, 2026, both of which were not present at December 31, 2025, suggesting an acquisition during the period. Total shareholders' equity decreased to $22,746 thousand from $55,548 thousand at year-end 2025. The company disclosed it is a non-accelerated filer and smaller reporting company. As of October 21, 2026, the registrant reported 34,047,688 shares of common stock outstanding. The common stock trades on The Nasdaq Stock Market LLC under the symbol NASDAQ:MVIS.

What Was Disclosed

MicroVision filed a 10-Q for the quarter ended September 30, 2026, disclosing higher revenue compared to year-ago periods, a nine-month net loss of $74,465 thousand, a reduced cash and investment position, and a materially higher share count resulting from stock sales and note conversions.